ClinicalTrials.gg
CompletedNCT00358358Updated Jan 20, 2017

Chronic Obstructive Pulmonary Disease Endpoints Study

A Phase 4 interventional study of Fluticasone Propionate/Salmeterol 500/50mcg combination and Fluticasone Propionate 500mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 11 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-01-20.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 4 under way, 1 of them phase 3. Fluticasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
24th of 59
163 · median 95
Started
2006
with 4 others
Phase 4
28 of 59
2 open now
Registered
6th of 59
by date
Lead sponsor
25 of 59
GlaxoSmithKline

Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, this one is the 24th largest by enrollment, is one of 5 that started in 2006, is one of 28 in phase 4, and was the 6th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study will last for approximately 14 weeks and will involve 5 visits. The study is being carried out to look at different ways of measuring the effect of drug treatment on COPD. COPD is a respiratory disease which can affect your breathing and daily life. Symptoms of COPD can include breathlessness, cough, and wheeze. COPD varies enormously from patient to patient. The effects of drug treatment are usually measured by conducting lung function tests (breathing tests) using a machine called a spirometer but this does not always provide a complete picture of how well your COPD is responding. In this study we therefore want to look at new and more sensitive ways of measuring COPD. The results of this research will help in the assessment of new drugs for COPD in the future.

Read the detailed description

Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Fluticasone Propionate/Salmeterol 500/50mcg combination (FSC 500/50) and its individual components, Fluticasone Propionate 500mcg (FP500) and Salmeterol 50mcg (SAL 50)

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • COPD
  • Impulse Oscillometry System
  • Computerized Tomography
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of
  • Current or ex-smoker at least 10 pack- years

Exclusion criteria

Exclusion criteria:

  • Diagnosis of asthma
  • Active respiratory disorder other than
  • Evidence of uncontrolled non-pulmonary disease
  • Carcinoma not in complete remission for last 5 years
  • Lung volume reduction surgery in previous 12 months
  • Nocturnal positive pressure for sleep apnea
  • Other inclusion and exclusion criteria will be evaluated at the first study visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
163 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Peripheral airway resistance measured by IOS

Secondary outcomes

  1. Airway wall thickness measured by CT scans

07

Study locations

11 sites
  • GSK Investigational Site
    Absecon, New Jersey 8201, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406-7108, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500691, Chile
  • GSK Investigational Site
    Valparaiso, Valparaíso 2341131, Chile
  • GSK Investigational Site
    Tartu, 51014, Estonia
  • GSK Investigational Site
    Barnaul, 656 045, Russian Federation
  • GSK Investigational Site
    Moscow, 105 077, Russian Federation
  • GSK Investigational Site
    Moscow, 105 229, Russian Federation
  • GSK Investigational Site
    Nizhnekamsk, 423570, Russian Federation
08

References and documents

Publications

  • Kreindler JL, Watkins ML, Lettis S, Tal-Singer R, Locantore N. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naive patients with COPD. BMJ Open Respir Res. 2016 Sep 8;3(1):e000151. doi: 10.1136/bmjresp-2016-000151. eCollection 2016. PubMed 27651909 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2006
First posted
Jul 31, 2006
Start
Mar 2006
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Last update
Jan 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00358358
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 31, 2006
Start date
Mar 2006
Primary completion
Feb 2007
Completion
Feb 2007
Last update
Jan 20, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate

Start the discussion